Medicare Administrator Establishes Reimbursement Coding Policy for Agendia’s Breast Cancer Recurrence Test MammaPrint®

Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California’s Part B Medicare administrator, has established coding guidelines for the company’s MammaPrint test. MammaPrint is Agendia’s FDA-cleared breast cancer recurrence test, which has been reimbursed by payors since 2008.

Source: Agendia